Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/943819/000094381918000016/rmd-20180930x10q.htm
January 2023
November 2022
October 2022
August 2022
July 2022
June 2022
June 2022
May 2022
April 2022
January 2022
Exhibit 99.1
For investors Amy Wakeham O: 858-836-5000 investorrelations@resmed.com |
For media Jayme Rubenstein O: 858-836-6798 news@resmed.com |
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2019
~ Strong year-over-year growth in revenue, net income, and earnings per share ~
~ Growth balanced across the entire product portfolio ~
Note: A webcast of ResMeds conference call will be available at 4:30 p.m. EDT today at http://investor.resmed.com
SAN DIEGO, October 25, 2018 ResMed Inc. (NYSE: RMD, ASX: RMD), a world-leading connected health company, today announced results for its quarter ended September 30, 2018.
First Quarter 2019 Highlights
| Revenue increased 12% to $588.3 million; up 13% on a constant currency basis |
| Net income increased by 23%; non-GAAP net income up 23% |
| GAAP diluted earnings per share of $0.73; non-GAAP diluted earnings per share of $0.81 |
Our first quarter 2019 results demonstrate continued strong performance across our business with 13 percent top-line revenue growth, driven by growth across our entire portfolio of offerings, said Mick Farrell, ResMeds chief executive officer. We also delivered another quarter of improving operating leverage resulting in double-digit growth at the bottom line.
Farrell continued, During the quarter we expanded our product portfolio with new masks and made ongoing upgrades to our digital health solutions, separating ResMed from the competition. We provide customers with services and solutions to help improve patient outcomes, create efficiencies, and reduce overall healthcare system costs.
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/943819/000094381918000016/rmd-20180930x10q.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Resmed Inc.
Resmed Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Resmed Inc provided additional information to their SEC Filing as exhibits
Ticker: RMD
CIK: 943819
Form Type: 10-Q Quarterly Report
Accession Number: 0000943819-18-000016
Submitted to the SEC: Thu Oct 25 2018 7:18:22 PM EST
Accepted by the SEC: Fri Oct 26 2018
Period: Sunday, September 30, 2018
Industry: Surgical And Medical Instruments And Apparatus